Scientists have found an association between shift work and COVID-19 positivity in hospitalised patients.
Using data from UK Biobank – the world’s largest biomedical database – shift work increased the likelihood of testing positive for COVID-19 in hospitalised patients 2-3 fold, depending on the nature of shift work. The effect persisted even after controlling for known COVID-19 risk factors.
The study involved researchers at The University of Manchester, Radcliffe Department of Medicine at The University of Oxford and the University of West Indies.
Supported by the NIHR Manchester Biomedical Research Centre, Medical Research Council and Wellcome Trust, it is published in the journal Thorax.
Share this article
FORT LAUDERDALE, Fla., Feb. 17, 2021 /PRNewswire/
ChronWell, Inc., a digital health and technology-enabled remote care management company, today announced that Stephen Harrison, MD, FACP, FAASLD, has been added to the company s Board of Advisors. I am excited about the prospect of working with the ChronWell team to further it s important work in using data and digital tools to help patients and practices together achieve better outcomes, said Dr. Harrison. With ChronWell s deep experience in harnessing clinical data, and scientific approach, I m anticipating great strides in digital healthcare in a variety of specialties, beginning with gastroenterology and liver disease.
Top colleges at Oxford are in the grip of unconscious bias training dailymail.co.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from dailymail.co.uk Daily Mail and Mail on Sunday newspapers.
You are here
Home » News » Early animal studies by Pirbright and Oxford yield promising results for new potential COVID-19 vaccine
Early animal studies by Pirbright and Oxford yield promising results for new potential COVID-19 vaccine Posted: 22 January, 2021
Studies carried out by The Pirbright Institute and the University of Oxford have shown that Oxford’s new potential vaccine against COVID-19, named RBD-SpyVLP, produces a strong antibody response in mice and pigs, providing vital information for the further development of the vaccine. Although this type of vaccine is not a competitor for the first wave of vaccines, it is hoped that it will be useful as a standalone vaccine or as a booster for individuals primed with a different COVID-19 vaccine.